Realta Life Sciences

Realta Life Sciences company information, Employees & Contact Information

ReAlta Life Sciences is a clinical-stage biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases. ReAlta’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND clearance by the U.S. Food and Drug Administration (FDA) for the treatment of acute exacerbations of chronic obstructive pulmonary disease and acute graft-versus-host disease, and IND clearance, Orphan Drug Designation, and Fast Track Designation by the FDA, and Orphan Drug Designation by the European Medicines Agency, for the treatment of hypoxic-ischemic encephalopathy (HIE). The company launched in 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com or contact us at info@realtalifesciences.com.

Company Details

Employees
31
Founded
-
Address
5665 Lowery Rd, Suite 100,puerto Rico
Phone
(757) 901-0460
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Palo Alto.
HQ
Norfolk, Virginia
Looking for a particular Realta Life Sciences employee's phone or email?

Realta Life Sciences Questions

News

ReAlta Life Sciences Announces Appointment of Biotechnology Leader Andrew Miller, Ph.D., to Board of Directors - FinancialContent

ReAlta Life Sciences Announces Appointment of Biotechnology Leader Andrew Miller, Ph.D., to Board of Directors FinancialContent

ReAlta Life Sciences Apoints Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board - citybiz

ReAlta Life Sciences Apoints Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board citybiz

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Accomplished Financial Executive - Business Wire

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Accomplished Financial Executive Business Wire

ReAlta Life Sciences Announces New Inflammatory Biomarker Data from Acute Exacerbations of Chronic Obstructive Pulmonary Disease Program at American Thoracic Society 2025 International Conference - Business Wire

ReAlta Life Sciences Announces New Inflammatory Biomarker Data from Acute Exacerbations of Chronic Obstructive Pulmonary Disease Program at American Thoracic Society 2025 International Conference Business Wire

Investigational Therapy for Hypoxic-Ischemic Encephalopathy Gets Orphan Drug Status - Medical Professionals Reference

Investigational Therapy for Hypoxic-Ischemic Encephalopathy Gets Orphan Drug Status Medical Professionals Reference

ReAlta Life Sciences Strengthens Management Team with the Appointment of Biotechnology Business Leader Ellen Lubman, MBA as Chief Business Officer - Business Wire

ReAlta Life Sciences Strengthens Management Team with the Appointment of Biotechnology Business Leader Ellen Lubman, MBA as Chief Business Officer Business Wire

Senator Mark Warner Visits ReAlta Life Sciences’ Biotech Research Facility, Highlights Importance of Rare Disease Innovation - Business Wire

Senator Mark Warner Visits ReAlta Life Sciences’ Biotech Research Facility, Highlights Importance of Rare Disease Innovation Business Wire

ReAlta Life Sciences to Present New Clinical Data from Hypoxic Ischemic Encephalopathy Program at Pediatric Academic Societies 2025 Meeting - Business Wire

ReAlta Life Sciences to Present New Clinical Data from Hypoxic Ischemic Encephalopathy Program at Pediatric Academic Societies 2025 Meeting Business Wire

ReAlta Life Sciences Receives EMA Orphan Drug Designation for RLS-0071 (pegtarazimod) for the Treatment of Graft-Versus-Host Disease - Business Wire

ReAlta Life Sciences Receives EMA Orphan Drug Designation for RLS-0071 (pegtarazimod) for the Treatment of Graft-Versus-Host Disease Business Wire

Top Realta Life Sciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant